Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.41 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.41 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 6/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4594814 | 0.88 | LMNA (0.59) | HPGDLMNAALDH1A1TSHRHSD17B10 | |
| Trifluoromethanesulfonic Acid SCHEMBL5744160 | 0.84 | HPGD (0.36) | HPGDLMNAALDH1A1TSHRHSD17B10 | |
| SCHEMBL17822053 | 0.82 | ERN1 (0.49) | HPGDLMNAALDH1A1TSHRHSD17B10 | |
| SCHEMBL17822006 | 0.78 | ERN1 (0.42) | ALDH1A1SMN1; SMN2GRIA1GRIA2GRIA3 | |
| SCHEMBL8525889 | 0.77 | ALDH1A1 (0.47) | HPGDLMNAALDH1A1TSHRHSD17B10 | |
| SCHEMBL17821930 | 0.76 | KDM4E (0.35) | HPGDLMNAALDH1A1TSHRHSD17B10 | |
| SCHEMBL17821932 | 0.76 | KDM4E (0.35) | HPGDLMNAALDH1A1TSHRHSD17B10 | |
| SCHEMBL9053578 | 0.76 | RARA (0.40) | HPGDLMNAALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL9055810 | 0.76 | RARA (0.40) | HPGDLMNAALDH1A1TSHRHSD17B10 | |
| SCHEMBL909951 | 0.75 | LMNA (0.42) | HPGDLMNAALDH1A1HSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-12-12 | — | — | US | disclosed |
| EP-3625228-B1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-07-07 | — | — | EP | disclosed |
| US-20210113559-A1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-04-22 | — | — | US | disclosed |
| EP-3625228-A1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2020-03-25 | — | — | EP | disclosed |
| US-20190111044-A1 | 2-PHENETHENYLTETRAHYDRO ISOQUINOLINES USEFUL AS ANTI-HIV COMPOUNDS | Prosetta Antiviral, Inc. | 2019-04-18 | — | — | US | disclosed |
| US-10195189-B2 | 2-phenethenyltetrahydro isoquinolines useful as anti-HIV compounds | Prosetta Antiviral, Inc. (US) | 2019-02-05 | — | — | US | disclosed |
| WO-2018210988-A1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-11-22 | — | — | WO | disclosed |
| US-20170368051-A1 | 2-PHENETHENYLTETRAHYDRO ISOQUINOLINES USEFUL AS ANTI-HIV COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-12-28 | — | — | US | disclosed |
| US-9518022-B2 | Anti-HIV compounds | PROSETTA ANTIVIRAL INC. (US) | 2016-12-13 | — | — | US | disclosed |
| WO-2016100391-A1 | 2-PHENETHENYLTETRAHYDRO ISOQUINOLINES USEFUL AS ANTI-HIV COMPOUNDS | Prosetta Antiviral, Inc. (US) | 2016-06-23 | — | — | WO | disclosed |
| US-8110681-B2 | Compounds for the treatment of spinal muscular atrophy and other uses | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110681-B2 | Compounds for the treatment of spinal muscular atrophy and other uses | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110681-B2 | Compounds for the treatment of spinal muscular atrophy and other uses | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-02-07 | — | — | US | disclosed |
| US-20090312323-A1 | COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HHS (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090312323-A1 | COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HHS (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090312323-A1 | COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HHS (US) | 2009-12-17 | — | — | US | disclosed |
| EP-2027088-A2 | COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | The Government of the United States of America, as repres. by the Secretary of Health and Human Services, Nat. Inst. of Health (US) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007109211-A2 | 1-OXO-ISOINDOLINE COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007109211-A2 | 1-OXO-ISOINDOLINE COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2007-09-27 | — | — | WO | disclosed |
| US-20060041123-A1 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190111044-A1 | 2-PHENETHENYLTETRAHYDRO ISOQUINOLINES USEFUL AS ANTI-HIV COMPOUNDS | MAVS, EIF2AK2, POLRMT | HPGD 1172/4885LMNA 3070/4885ALDH1A1 3748/4885 |
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | HPGD 135/4885LMNA 4601/4885ALDH1A1 468/4885 |
| US-20210113559-A1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | PTGER1, PTGER4, PTGER2 | HPGD 135/4885LMNA 4601/4885ALDH1A1 468/4885 |
| US-10195189-B2 | 2-phenethenyltetrahydro isoquinolines useful as anti-HIV compounds | MAVS, EIF2AK2, POLRMT | HPGD 1172/4885LMNA 3070/4885ALDH1A1 3748/4885 |
| US-20060041123-A1 | Antibacterial agents | NQO2, NRDC, IFNG | HPGD 632/4885LMNA 2488/4885ALDH1A1 3099/4885 |
| US-20090312323-A1 | COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | SMN1; SMN2, RNMT, CPT1B | HPGD 2045/4885LMNA 622/4885ALDH1A1 1547/4885 |
| US-20170368051-A1 | 2-PHENETHENYLTETRAHYDRO ISOQUINOLINES USEFUL AS ANTI-HIV COMPOUNDS | MAVS, EIF2AK2, POLRMT | HPGD 1172/4885LMNA 3070/4885ALDH1A1 3748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.